Trinity Biotech (TRIB)
(Real Time Quote from BATS)
$0.90 USD
+0.08 (10.04%)
Updated Aug 5, 2025 03:39 PM ET
After-Market: $0.90 0.00 (0.00%) 4:06 PM ET
5-Strong Sell of 5 5
F Value C Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TRIB 0.90 +0.08(10.04%)
Will TRIB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TRIB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TRIB
Trinity Biotech Shares Surge on Positive Pre-Pivotal Clinical CGM Trial
Trinity Biotech's Stock Rises After Acquisition of Metabolomics
TRIB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Trinity Biotech Stock Gain From Its Latest Patent Process?
Other News for TRIB
Micro Cap Surges Following WHO Approval
Trinity Biotech Unveils CGM+: An AI-Native Platform Targeting the $260 Billion AI Wearable ...
Trinity Biotech (TRIB) Launches CGM+, an Advanced AI-Driven Biosensor Platform | TRIB Stock News
Trinity Biotech unveils CGM+, next-gen wearable biosensor platform
12 Health Care Stocks Moving In Thursday's After-Market Session